Brief: GT Biopharma Q2 Basic EPS USD -0.05
GT Biopharma Inc expected to post a loss of 10 cents a share - Earnings Preview
GT Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: GT Biopharma Reports First Quarter 2023 Financial Results
GT Biopharma Inc expected to post a loss of 14 cents a share - Earnings Preview
GT Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: GT Biopharma Reports Fourth Quarter And Full-Year 2022 Financial Results And Provides Corporate Update
GT Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Gt Biopharma Inc - On February 22, 2023, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: GT Biopharma Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
Brief: GT Biopharma Names Jeff Miller As Consulting Chief Medical Officer
Brief: Gt Biopharma Reports Q3 Fiscal 2022 Results
Brief: GT Biopharma Files For Mixed Shelf Of Upto $150 Mln
Brief: GT Biopharma Announces Adjournment Of Special Shareholders Meeting
Brief: GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
GT Biopharma Inc reports results for the quarter ended in June - Earnings Summary
GT Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Gt Biopharma Presents Preclinical Data Demonstrating Second-Generation Cd19 Targeting Tri-Specific Killer Engager Driving Robust Nk Cell Function Against B Cell Malignancies
GT Biopharma Inc reports results for the quarter ended in March - Earnings Summary